You are here

  • Home
  • Archive
  • Volume 77, Issue 2
  • Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Article metrics

Article menu

Download PDFPDF

XML
Clinical and epidemiological research
Extended report
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

 

Online download statistics by month:

Online download statistics by month: October 2017 to May 2023

AbstractFullPdf
Oct 201710961118386
Nov 2017499524278
Dec 2017412413154
Jan 2018629631244
Feb 2018430417236
Mar 2018307304154
Apr 2018206207142
May 201820220388
Jun 201817017358
Jul 201815715765
Aug 201822822883
Sep 2018210210109
Oct 201823923985
Nov 201816816867
Dec 201817317367
Jan 201914413988
Feb 201915314874
Mar 201914413668
Apr 2019949369
May 201911211294
Jun 2019787887
Jul 201913512890
Aug 20191019282
Sep 2019908474
Oct 2019129119112
Nov 2019848361
Dec 2019888572
Jan 202012612068
Feb 20201059363
Mar 2020595757
Apr 20209586115
May 2020888077
Jun 2020565161
Jul 2020766458
Aug 2020595271
Sep 2020897759
Oct 2020766868
Nov 2020887376
Dec 2020947549
Jan 2021676068
Feb 2021625656
Mar 2021685866
Apr 2021534662
May 2021605254
Jun 2021554852
Jul 2021444150
Aug 2021675158
Sep 2021756948
Oct 2021625466
Nov 2021685469
Dec 2021595549
Jan 2022645937
Feb 2022484736
Mar 2022696225
Apr 2022848031
May 2022767530
Jun 2022645720
Jul 2022534528
Aug 2022625820
Sep 2022838128
Oct 2022847522
Nov 2022403636
Dec 2022504515
Jan 2023524723
Feb 2023706019
Mar 2023434014
Apr 2023403519
May 202339739217
Total960892965127